2. Academic Validation
  3. Development of Selective PARP1 Inhibitors for Treatment of Cancer

Development of Selective PARP1 Inhibitors for Treatment of Cancer

  • ACS Med Chem Lett. 2025 Sep 26;16(10):1914-1917. doi: 10.1021/acsmedchemlett.5c00536.
Xin Zhou 1,  Steven H Liang 1
Affiliations

Affiliation

  • 1 Department of Radiology and Imaging Sciences, Emory University, 1364 Clifton Road, Atlanta, Georgia 30322, United States.
PMID: 41089499 DOI: 10.1021/acsmedchemlett.5c00536
Abstract

Poly-(ADP-ribose) polymerase 1 (PARP1) is a critical member of the PARP enzyme family, responsible for the majority of poly-(ADP-ribosyl)-ation activity in response to DNA damage. The development of highly selective PARP1 inhibitors is paramount for next-generation Cancer therapeutics to mitigate the adverse effects caused by inhibition of Other PARP subtypes. This patent disclosed compounds demonstrate exceptional selectivity for PARP1 over PARP2, which is promising for further clinical research.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-178468
    PARP1 Inhibitor